Top Markets
Coin of the day
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc.

AMBS
Rangering i aksjer #41182
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Aksjekurs
$0.0001
Sist synkronisert: 2026-08-11
Markedsverdi
$36.84K
Endring (1 dag)
0.00%
Endring (1 år)
-66.67%
Land
US
Handel Amarantus BioScience Holdings, Inc. (AMBS)

Kategori

Pris AMBS pris med markedsverdi på B
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
AMBS
$0.0001
Markedsverdi av Amarantus BioScience Holdings, Inc.(AMBS)
Markedsverdi: $36.84K
Per August 2026 har Amarantus BioScience Holdings, Inc. en markedsverdi på $36.84K. Dette gjør Amarantus BioScience Holdings, Inc. til det 41182nd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Amarantus BioScience Holdings, Inc. fra 2010 til 2026
AMBS sammenlignet med topp 5 mest populære stocks
Pris på AMBS Eiendel B Markedsverdi for B Resultater
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$14,612.41 $36.84K
$5.383T +14,612,413,949.56%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$12,006.71 $36.84K
$4.423T +12,006,707,654.24%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$11,292.77 $36.84K
$4.160T +11,292,769,909.18%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$9,943.60 $36.84K
$3.663T +9,943,597,622.65%
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.
$7,847.86 $36.84K
$2.891T +7,847,856,351.78%